Liraglutide combination with rosiglitazone and metformin evaluated for glycemic control in Type 2 Diabetes

Managing Type 2 Diabetes (T2DM) often requires combination therapy to achieve optimal glycemic control and prevent complications. While metformin is a first-line agent, many patients require additional therapies. Thiazolidinediones like rosiglitazone improve insulin sensitivity, but their combination with GLP-1 receptor agonists like liraglutide, alongside metformin, represents a multi-pronged approach to target different aspects of T2DM pathophysiology. This trial aimed to determine the efficacy and safety of adding Liraglutide to an existing regimen of rosiglitazone and metformin, addressing the need for improved glucose management in patients already on oral hypoglycemic agents.

This Phase 3, randomized clinical trial (NCT00333151) enrolled 576 subjects with Type 2 Diabetes who were previously treated with oral hypoglycemic agents. The study compared the effect on glycemic control of Liraglutide in combination with rosiglitazone plus metformin versus rosiglitazone plus metformin alone. The primary endpoint was the effect on glycemic control, with safety and tolerability also being assessed. The trial was conducted in the United States, Europe, and Oceania, sponsored by Novo Nordisk A/S, and completed in August 2007.